Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304114 | 0.82 | PDE10A (0.65) | PDE10ACSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL1302496 | 0.78 | PDE10A (0.50) | PDE10A | |
| SCHEMBL1304364 | 0.77 | PDE10A (0.53) | PDE10A | |
| SCHEMBL2494438 | 0.74 | PDE10A (0.67) | PDE10ACSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL2482809 | 0.74 | P2RX3 (0.43) | — | |
| SCHEMBL2490704 | 0.72 | PDE10A (0.49) | PDE10ACSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL2488508 | 0.71 | PDE10A (0.64) | PDE10ACSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL3321188 | 0.70 | PDE10A (0.62) | PDE10ACSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL5695252 | 0.69 | ADRA2A (0.44) | KDRKDM4E | |
| Hydrochloric Acid SCHEMBL6497666 | 0.68 | ADRA2A (0.43) | KDRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053438-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053438-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | PDE10A 1/4885CSNK1A1 3388/4885CSNK1D 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.